arginine has been researched along with Cancer of Lung in 204 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 47 (23.04) | 18.7374 |
1990's | 71 (34.80) | 18.2507 |
2000's | 47 (23.04) | 29.6817 |
2010's | 23 (11.27) | 24.3611 |
2020's | 16 (7.84) | 2.80 |
Authors | Studies |
---|---|
Chen, W; Hou, R; Li, Q; Liang, H; Yang, Y; Zhang, Y | 1 |
Azuma, K; Hoshino, T; Imaizumi, A; Ishii, H; Karakawa, S; Kasajima, R; Kato, Y; Kawahara, A; Kikuchi, S; Matsuo, N; Miyagi, Y; Murotani, K; Sasada, T; Tagami, T; Tokito, T; Xiang, H | 1 |
Auzanneau, C; Barlesi, F; Besse, B; Bessede, A; Bodet, D; Cabart, M; Chaput, N; Chomy, F; Cousin, S; Danlos, FX; Even, C; Fontan, L; Guégan, JP; Italiano, A; Khettab, M; Le Loarer, F; Marabelle, A; Nafia, I; Peyraud, F; Planchard, D; Roubaud, G; Soria, JC; Tselikas, L | 1 |
Chong, HC; Chung, SF; Kim, CF; Lee, LM; Leung, YC; Tam, SY | 1 |
Dai, J; Fan, J; Gu, Y; Hu, Z; Jin, G; Ma, H; Qin, N; Shen, H; Sun, Q; Zhang, C; Zhang, E; Zhang, X; Zhu, M | 1 |
DI, LQ; Huang, X; Lu, YY; Luo, ZC; Qi, MY; Shan, JJ; Zhang, W | 1 |
Chen, X; Liu, J; Liu, S; Yang, Y; Ye, G | 1 |
Lian, C; Ma, H; Shi, S; Wang, D; Wang, Z; Zhang, J; Zhang, Q; Zuo, C | 1 |
Chen, M; Jia, B; Li, Y; Liu, X; Liu, Y; Ma, T | 1 |
Gao, J; Guo, B; Hu, C; Long, H; Shu, C; Wang, X; Yang, F; Zha, H; Zhou, L; Zhu, B | 1 |
Chen, YW; Chong, HC; Chung, SF; Kim, CF; Kwok, SY; Leung, SL; Leung, YC; Lo, WH; So, PK; Tam, SY; Wong, KY | 1 |
Bakan, F; Cakmak, MC; Cokol, M; Denkbas, EB; Kara, G; Parlar, A | 1 |
Cai, C; Feng, XH; Gu, S; Shen, L; Yang, B; Yu, Y; Yuan, B; Zhang, H; Zhu, Y | 1 |
Angelico, G; Broggi, G; Caltabiano, R; Filetti, V; Ledda, C; Lombardo, C; Loreto, C; Rapisarda, V; Vitale, E | 1 |
Billingham, L; Gaskell, C; Gaunt, C; Jackson, A; Pascoe, J; Steven, N; Thompson, J | 1 |
Ali, A; Başak Türkmen, N; Burr, K; Cao, HW; Cao, JR; Chan, JCY; Chen, J; Chen, Y; Christensen, BB; Çiftçi, O; Connelly, CD; de Mol, BA; Doğan, MF; Donahoe, LL; Dungchai, W; Fan, FF; Foldager, CB; Garvin, JL; Gonzalez-Vicente, A; Guan, J; He, P; Hede, KTC; Henry, CS; Hesek, A; Hong, NJ; Hossain, MJ; Huang, J; Huang, K; Hussain, S; Ishii, Y; Jeelani, SUY; Jiang, W; Keith, JP; Kelder, JC; Keshavjee, S; Khachornsakkul, K; Khadim, A; Kobayashi, N; Levenbrown, Y; Li, Y; Lim, SK; Lind, MC; Liu, H; Liu, X; Liu, Y; Lu, L; Luo, L; Lyu, CJ; Ma, Y; Mei, LH; Meredith, SC; Musharraf, SG; Nitin, N; Olesen, ML; Phoonsawat, K; Qian, G; Ratnarathorn, N; Ren, M; Saez, F; Şahin, Y; Scherpelz, KP; Shaffer, TH; Sun, G; Swinkels, BM; Taşlıdere, A; Ten Berg, JM; Thomsen, JS; Toh, WS; van Boven, WJ; Vermeulen, FE; Waddell, TK; Wang, HP; Wang, S; Wang, Z; Wei, B; Wickramasinghe, A; Woods, LM; Xiao, Y; Xu, C; Yamazaki, T; Yang, M; Yang, X; Yao, LL; Yasufuku, K; Yin, S; Yu, T; Zareena, B; Zhang, R; Zhuo, X | 1 |
Cheng, PN; Ho, JC; Lam, SK; Li, YY; U, KP; Xu, S | 1 |
Cheng, PN; Ho, JC; Lam, SK; Xu, S | 1 |
Dziadziuszko, R; Jablonska, P; Kutryb-Zajac, B; Mierzejewska, P; Polanska, J; Rzyman, W; Sitkiewicz, M; Slominska, EM; Smolenski, RT | 1 |
Berrett, KC; Bomalaski, JS; Chalishazar, MD; Cosulich, SC; DeBerardinis, RJ; Gertz, J; Guthrie, MR; Hu, Z; Huang, F; Ingolia, NT; Ireland, AS; Kudla, M; Lee, Y; Lum, DH; Modzelewska, K; Mukhopadhyay, A; Oliver, TG; Schuman, SS; Vahrenkamp, JM; Wait, SJ; Wang, G | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T | 1 |
Gerber, SA; Rigas, JR; Schweppe, DK | 1 |
Attili, VS; Jamil, K; Madireddy, UR; Natukula, K; Pingali, UR | 1 |
Avasarala, S; Bikkavilli, RK; Borgia, JA; DeGregori, J; Karuppusamy Rathinam, MK; Pergande, MR; Port, JD; Van Scoyk, M; Winn, RA; Zerayesus, S; Zhang, W; Zhao, X | 1 |
Karnaushenko, OV; Milinevska, OA; Samoilenko, ОА; Shlyakhovenko, VA; Zaletok, SP | 1 |
Lee, RJ; Li, Y; Teng, L; Wang, X | 1 |
Bartter, T; Deutz, NE; Engelen, MP; Koeman, F; Safar, AM | 1 |
Chen, H; Gupta, V; Lorton, B; Shechter, D | 1 |
Chelala, C; Freitas, MO; Ghazaly, E; Lattanzio, L; Lo Nigro, C; Locke, M; Martin, SA; Mitsinga, M; Nagano, A; Szlosarek, P; Wang, J | 1 |
Hsia, TC; Mong, MC; Yin, MC | 1 |
Avril, NE; Beck, S; Bomalaski, JS; Butcher, L; Crook, T; Dancey, G; Ellis, S; Fennell, D; Gilligan, D; Hackshaw, A; Hillman, P; Johnston, A; Lawrence, C; Lemoine, N; Lind, M; Luong, P; Mitra, S; Nolan, L; Payne, S; Phillips, MM; Rudd, RM; Schmid, P; Shamash, J; Sheaff, MT; Spicer, J; Steele, JP; Szlosarek, PW; Szyszko, T; Taylor, P; Thomson, J; Tomsa, M; Wu, BW | 1 |
Lin, R; Ling, YH; Perez-Soler, R | 1 |
Gunduz, M; Mita, Y; Naomoto, Y; Ouchida, M; Sakai, A; Shimizu, K; Tanabe, S; Toyooka, S; Yamamoto, H; Yasuda, Y | 1 |
Baek, KH; Choi, JJ; Han, SE; Huh, JH; Kim, JS; Kim, K; Kim, MS; Kwon, IC; Lee, HY; Noh, SM; Oh, YK; Park, MO; Shim, G | 1 |
Field, HI; Hamamoto, R; Hayami, S; Kelly, JD; Maehara, Y; Nakamura, Y; Neal, DE; Ponder, BA; Toyokawa, G; Tsunoda, T; Unoki, M; Yoshimatsu, M | 1 |
Bauerfeind, U; Knüttgen, D; Lange, J; Sakka, SG; Stoelben, E; Wappler, F | 1 |
Colley, KJ; Zapater, JL | 1 |
Bomalaski, J; Elgart, G; Feun, LG; Jungbluth, AA; Kuo, MT; Marini, A; Moffat, F; Rodgers, SE; Savaraj, N; Sisson, W; Walker, G; Wangpaichitr, M; Wu, CJ; You, M | 1 |
Kumar, A; Kumar, S; Mathur, N; Pant, MC; Tilak, AR | 1 |
Papadakis, ED; Soulitzis, N; Spandidos, DA | 1 |
Fu, J; Li, F; Li, S; Peng, S; Wu, D; Yu, G | 1 |
Christiani, DC; Liu, G; Lynch, TJ; Miller, DP; Park, S; Su, L; Wain, JC; Xu, LL; Zhou, W | 1 |
Christiani, DC; Fan, R; Liu, G; Lynch, TJ; Miller, DP; Sai, Y; Su, L; Thurston, SW; Wain, JC; Zhou, W | 1 |
Hamajima, N; Ito, H; Kang, D; Lee, KM; Matsuo, K; Mitsudomi, T; Saito, T; Sato, S; Sugiura, T; Tajima, K; Ueda, R; Yasue, T; Yoo, KY | 1 |
Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W | 1 |
Cabrera, W; Dragani, TA; Falvella, FS; Galbiati, F; Galvan, A; Ibanez, O; Mancuso, MT; Manenti, G; Pazzaglia, S; Pignatiello, C; Saran, A; Spinola, M; Zaffaroni, D | 1 |
Bussolati, O; Dall'Asta, V; Gazzola, GC; Rotoli, BM; Sala, R | 1 |
Ahrendt, SA; Hu, Y; McDermott, MP | 1 |
Bencko, V; Boffetta, P; Borel, S; Brennan, P; Canzian, F; Chabrier, A; Fabianova, E; Foretova, L; Hall, J; Hung, RJ; Janout, V; Lissowska, J; Mates, D; Rudnai, P; Szeszenia-Dabrowska, N; Zaridze, D | 1 |
Fanikos, JR; Kubiak, DW; Szumita, PM | 1 |
Guo, L; Li, J; Ma, Y; Vogel, U; Wang, H; Yin, J | 1 |
Dager, W; Spinler, SA | 1 |
Beloussow, K; Shen, LJ; Shen, WC | 1 |
Borg, A; Dziadziuszko, R; Jassem, E; Jassem, J; Kobierska-Gulida, G; Limon, J; Rzyman, W; Szymanowska, A | 1 |
Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H | 1 |
Jia, G; Jin, Y; Liu, N; Liu, SW; Liu, YQ; Yan, L; Zhao, XH | 1 |
Bartsch, H; Butkiewicz, D; Dienemann, H; Edler, L; Muley, T; Popanda, O; Risch, A; Schattenberg, T; Schmezer, P; Waas, P | 1 |
Agulnik, JS; Batist, G; Chong, G; Cohen, V; Jarry, J; Kreisman, H; Miller, WH; Small, D; Tejada, NA | 1 |
Bessho, A; Hotta, K; Kiura, K; Segawa, Y; Shinkai, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S | 1 |
Kaur, P; Pachouri, SS; Singh, J; Sobti, RC | 1 |
Bridle, H; Eisen, T; El Galta, R; Houlston, RS; Matakidou, A; Rudd, MF; Webb, EL | 1 |
Brinkley, BR; Cai, WW; Caulin, C; Goepfert, TM; Lang, GA; Lozano, G; Nguyen, T; Roop, DR | 1 |
Fukui, T; Furuta, K; Kunitoh, H; Matsuno, Y; Nokihara, H; Ohe, Y; Sakamoto, H; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Tsuta, K; Yamamoto, N; Yoshida, T | 1 |
Andreassen, T; Ekstrøm, PO; Haugen, A; Lind, H; Ryberg, D; Skaug, V; Stangeland, L; Zienolddiny, S | 1 |
Deppert, W; Heinlein, C; Krepulat, F; Löhler, J; Speidel, D; Tolstonog, GV | 1 |
Boldrini, L; Fontanini, G; Gisfredi, S; Greco, G; Lucchi, M; Mussi, A; Ursino, S | 1 |
de Villiers, EM; Fei, JW | 1 |
Bannai, K; Ishigaki, S; Ishii, B; Kogawa, K; Kohgo, Y; Koshida, Y; Kumai, R; Mogi, Y; Niitsu, Y; Urushizaki, I | 1 |
Bhide, SV; Maru, GB | 1 |
Bhide, SV; Maru, GB; Sawai, MM | 1 |
Dong, Z; Fidler, IJ; Gutman, M; Huang, S; Juang, SH; Nathan, C; Xie, K; Xie, QW | 1 |
Becker, RP; Dragović, T; Erdös, EG; Schraufnagel, DE; Sekosan, M; Votta-Velis, EG | 1 |
Bai, TR; Bramley, AM | 1 |
Akedo, H; Kosaka, H; Nishizawa, Y; Seiyama, A; Shiga, T; Tanaka, H; Terada, N; Yamamoto, T | 1 |
Lala, PK; Orucevic, A | 1 |
Kimura, H; Kimura, M; Murata, M; Saisho, H; Tagawa, M; Watanabe, S | 1 |
Cendan, JC; Edwards, P; Lind, DS; MacKay, S; Moldawer, LL; Topping, DB | 1 |
Corbella, J; Estape, J; Firvida, J; Fuentes, M; Galan, C; Gene, M; Gomez-Catalan, J; Huguet, E; Rodamilans, M; To-Figueras, J | 1 |
De Ley, M; Haelewyn, J; Hoylaerts, MF; Michiels, L; Verhaert, P; Witters, R | 1 |
Akedo, H; Kosaka, H; Nishizawa, Y; Seiyama, A; Terada, N; Yamamoto, T | 1 |
Fujisawa, T; Kakisawa, K; Kimura, H; Murata, M; Shirasawa, H; Tagawa, M | 1 |
Faller, DV; Fingeroth, J; Mentzer, SJ; Perrine, SP; Reilly, JJ | 1 |
de la Cuesta, RS; Donahoe, PK; Kurian, MS; MacLaughlin, DT; Manganaro, TF; Waneck, GL | 1 |
Khanna, N; Swaminathan, S | 1 |
Blanck, G; Eason, DD; Shepherd, AT | 1 |
Pham, HT; Ruediger, R; Walter, G | 1 |
Faller, DV; Mentzer, SJ; Perrine, SP | 1 |
Xu, Q; Zhang, XM | 1 |
Christiani, DC; Fan, R; Liu, G; Lynch, TJ; Miller, DP; Su, L; Thurston, SW; Wain, JC; Xu, LL; Zhou, W | 1 |
Giga-Hama, Y; Goto, H; Isoai, A; Kumagai, H; Ueno, Y | 1 |
Atagi, S; Fukuta, K; Ogura, T; Sone, S | 1 |
Gabrielli, F; Tsugita, A | 1 |
Abe, M; Adachi, H; Imura, T; Inoue, T; Narabayashi, I; Ono, K; Onoyama, Y; Tanaka, Y; Yoshikawa, Y | 1 |
Bhoopalam, N; Robertson, GL; Zelkowitz, LJ | 1 |
Landon, J; Ratcliffe, JG; Rees, LH; Scott, AP | 1 |
Farbiszewski, R; Rzeczycki, W | 1 |
Utiger, RD | 2 |
Greenblatt, M; Lijinsky, W | 1 |
Farbiszewski, R; Rzeczycki, W; Worowski, K | 1 |
Kellen, JA; Lustig, V | 1 |
Murase, T; Saito, T; Yoshida, S | 1 |
Weisburger, JH; Yamamoto, RS | 1 |
Fairchild, DG; Jones, LD; Morse, WC | 1 |
Cardona, AF; Reveiz, L; Rueda, JR | 1 |
Blum, RH; Ettinger, DS; Finkelstein, DM; Lincoln, ST; Ritch, PS | 1 |
Fan, Y; Huang, ZY; Sun, L; Zhang, YP | 1 |
Bunn, PA; Simon, GR | 1 |
Yue, X; Zang, QC | 1 |
Beijnen, JH; Bussink, J; Huitema, AD; Punt, CJ; Timmer-Bonte, JN; Tjan-Heijnen, VC; van Die, CE; vd Heijden, HF | 1 |
Creech, RH; Ettinger, DS; Ferraro, JA; Ruckdeschel, JC; Tritchler, D; Vogl, SE; Woll, J | 1 |
Bork, E; Dombernowsky, P; Hansen, HH; Osterlind, K; Pedersen, AG | 1 |
Bruckman, JE; Burgert, EO; Evans, RG; Gilchrist, GS; Pritchard, DJ; Smithson, WA | 1 |
Calciati, A; Conte, PF; Giaccone, G; Musella, R | 1 |
Płuzańska, A; Robak, T | 1 |
Brattain, MG; Long, BH; Musial, ST | 3 |
Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL | 1 |
Broggini, M; Colombo, T; D'Incalci, M | 1 |
Dombernowsky, P; Hansen, HH; Nissen, NI; Pedersen, AG | 1 |
Eguchi, K; Etou, H; Miyachi, S; Morinari, H; Nakada, K; Noda, K; Ohkuni, Y; Saijo, N; Watanabe, K; Yamada, Y | 1 |
Eguchi, K; Etou, H; Miyachi, S; Morinari, H; Nakada, K; Noda, K; Ohe, Y; Ohkuni, Y; Watanabe, K; Yamada, Y | 1 |
Alberto, P; Bacchi, M; Cerny, T; Hürny, C; Joss, RA; Leyvraz, S; Ludwig, C; Martinelli, G; Stahel, R; Thürlimann, B | 1 |
Kang, S; Li, J; Li, L | 1 |
Grant, SC; Kris, MG | 1 |
Gromova, II; Razin, SV; Thomsen, B | 1 |
Ettinger, DS | 1 |
Ardizzoni, A; Giaccone, G; Haaxma-Reiche, H; Kirkpatrick, A; Postmus, PE; Quoix, E; Sahmoud, T; Smit, EF; van Zandwijk, N | 1 |
Blanc-Jouvan, F; Brambilla, C; Moro, D; Mousseau, M; Nagy-Mignotte, H; Orfeuvre, H; Schaerer, R | 1 |
Muggia, FM | 1 |
Aapro, M; Alberto, P; Bauer, J; Leyvraz, S; Michel, G; Stahel, R | 1 |
Burghouts, JT; Haaxma-Reiche, H; Postmus, PE; van der Graaf, WT | 1 |
de Jong, S; de Vries, EG; Kooistra, AJ; Mulder, NH; Zijlstra, JG | 1 |
Gemba, K; Kiura, K; Matsumura, T; Moritaka, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H | 1 |
Corringham, R; Corringham, S; Dhaliwal, H; Germond, C; Goss, GD; Rowen, J; Vincent, M | 1 |
Burghouts, J; Clerico, M; Dautzenberg, B; Festen, J; Giaccone, G; Kho, GS; Kirkpatrick, A; Sahmoud, T; Sörenson, S; Splinter, TA; van Zandwijk, N | 1 |
Blum, R; Bonomi, P; Chang, AY; Smith, JL; Smith, TJ; Tu, ZN; Wiernik, PH | 1 |
Campling, BG; Jain, N; Lam, YM; Pym, J | 1 |
Bergman, B; Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Kristjansen, PE; Lassen, U; Osterlind, K; Sigsgaard, TC | 1 |
Debruyne, C; Giaccone, G; Postmus, PE; Sahmoud, T; Splinter, TA; van Zandwijk, N | 1 |
de Vries, EG; Keith, WN; Mulder, NH; Nienhuis, EF; Uges, DR; van der Graaf, WT; Withoff, S | 1 |
Ardizzoni, A; Debruyne, C; Diaz-Puente, M; Giaccone, G; Postmus, PE; Scagliotti, G; Splinter, TA; Van Meerbeeck, J; Van Zandwijk, N | 1 |
Beltran, GS; Canfield, VA; Crowley, JJ; Grozea, PN; Kingsbury, L; Laufman, LR; Livingston, RB; Ross, SW; Weiss, GR | 1 |
Cascinu, S; Catalano, G; Del Ferro, E; Graziano, F; Ligi, M | 1 |
Cellerino, R; Cetto, G; Graziano, F; Isidori, P; Mari, D; Pasini, F; Santo, A; Tummarello, D | 1 |
Ghaemmaghami, M; Jett, JR | 1 |
Lokich, JJ | 1 |
Curran, D; Debruyne, C; Giaccone, G; Kho, GS; Lianes, P; Pennucci, MC; Postmus, PE; Sahmoud, T; Scagliotti, G; Splinter, TA; van Hoesel, Q; van Meerbeeck, J; van Zandwijk, N | 1 |
Mihara, K; Nagai, N; Ogata, H; Sasaki, Y; Shikii, T | 1 |
Betti, M; Corgna, E; Crinò, L; Darwish, S; Meacci, ML; Minotti, V; Palladino, MA; Tonato, M | 1 |
de Jong, RS; de Vries, EG; Groen, HJ; Höppener, FJ; Mulder, NH; Sleijfer, DT; Uges, DR; van der Graaf, WT; Willemse, PH | 1 |
Boogerd, W; van der Sande, JJ; van Zandwijk, N | 1 |
Jin, X; Liu, Z; Luo, B; Yin, L; Zeng, P | 1 |
Annemans, L; Giaccone, G; Vergnenègre, A | 1 |
Clerico, M; Curran, D; Giaccone, G; Gregor, A; Groen, HJ; Haaxma-Reiche, H; Karnicka, H; Kirkpatrick, A; Lewinski, T; Postmus, PE; Sahmoud, T; Smit, EF; van Meerbeeck, J | 1 |
Belani, CP; Calvo, AR | 1 |
Dingemans, AC; Giaccone, G; Postmus, PE; Scagliotti, GV; Span, S; van Ark-Otte, J; van der Valk, P | 1 |
Bergman, AM; Jensen, PB; Munch-Petersen, B; Peters, GJ; Pinedo, HM; Sehested, M; Smid, K; Veerman, G; Voorn, DA | 1 |
Dombernowsky, P; Hansen, HH; Hirsch, FR; Ingeberg, S; Jeppesen, N; Kristensen, C; Osterlind, K; Sorensen, PG | 1 |
Fietkau, R | 1 |
Yao, H; Zhou, J; Zhu, Q | 1 |
Wang, L; Yang, H; Ye, M | 1 |
Baker, LH; Fraile, RJ; Samson, MK; Talley, RW | 1 |
Bunn, PA; Ihde, DC; Radice, PA | 1 |
Henney, JE; Muggia, FM; Rozencweig, M; Von Hoff, DD | 1 |
Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Palangie, T; Parrot, R; Poisson, M; Pouillart, P | 1 |
Barouh, M; Carpentier, Y; Cattan, A; Cattan, E; Pourny, C | 1 |
Beck, H; Capranico, G; Gazdar, AF; Giaccone, G; Zunino, F | 1 |
Bergman, B; Sörenson, S; Sullivan, M | 1 |
Kohn, KW; Orr, A; Pommier, Y; Riou, JF | 1 |
Berendsen, HH; Ousterhuis, BE; Postmus, PE; Sleijfer, DT; Smit, EF | 1 |
Bork, E; Dombernowsky, P; Hansen, HH; Hansen, M | 1 |
Corringham, R; Corringham, S; Dhaliwal, H; Germond, C; Goss, GD; Kane, G; Rowen, J; Sinoff, C; Vincent, M | 1 |
Giaccone, G | 1 |
Berendsen, HH; Haaxma-Reiche, H; Postmus, PE; Sleijfer, DT; Smit, EF | 1 |
Dalesio, O; Giaccone, G; Kirkpatrick, A; McVie, JG; Splinter, TA; van Zandwijk, N | 1 |
Lorico, A; Rappa, G; Sartorelli, AC | 1 |
Cellerino, R; Cetto, G; Isidori, P; Pasini, F; Tummarello, D | 1 |
Donadio, M; Giaccone, G; Iberti, V; Testore, F | 1 |
Bergman, B; Bork, E; Dombernowsky, P; Ersbøll, J; Hansen, HH; Hansen, M | 1 |
Donadio, M; Giaccone, G; Iberti, V | 1 |
Jakobsen, A; Nielsen, K; Schultz, H; Steenholdt, S; Sørensen, BT | 1 |
Brattain, MG; Casazza, AM; Long, BH; Lorico, A; Wang, L; Wang, RC | 1 |
Calciati, A; Giaccone, G; Schmidt, G | 1 |
Bach, F; Dombernowsky, P; Hansen, HH; Sørensen, JB | 1 |
D'Incalci, M; Figoli, F; Montaldo, PG; Sorio, R; Tirelli, U; Zanette, ML; Zucchetti, M | 1 |
Cellerino, R; Di Furia, L; Gramazio, A; Guidi, F; Menichetti, E; Tummarello, D | 1 |
Berg, D; Blancy, E; Bugat, R; Canal, P | 1 |
McVie, G; Muggia, FM | 1 |
D'Incalci, M; Figoli, F; Lestuzzi, C; Monfardini, S; Sorio, R; Tirelli, U; Urso, R; Zanette, ML | 1 |
Christensen, IJ; Hansen, HH; Roed, H; Spang-Thomsen, M; Vindeløv, LL | 1 |
Bonardi, GM; Calciati, A; Donadio, M; Giaccone, G; Testore, F | 1 |
Bonardi, G; Calciati, A; Donadio, M; Giaccone, G; Testore, F | 1 |
Brunner, KW; Cerny, T; Joss, RA; Pedrazzini, A | 1 |
Berendsen, HH; Haaxma-Reiche, H; Postmus, PE | 1 |
Bork, E; Dombernowsky, P; Hansen, HH; Hansen, M; Hansen, SW; Pedersen, AG | 1 |
Eguchi, K; Morinaga, S; Saijo, N; Sakurai, M; Sano, T; Sasaki, Y; Shinkai, T; Suga, J; Tamura, T | 1 |
Bagatella, M; Bonardi, G; Calciati, A; Ciuffreda, L; Donadio, M; Ferrati, P; Giaccone, G | 1 |
Amato, G; Broggini, M; Colombo, T; D'Incalci, M; Erba, E; Vaghi, M | 1 |
Bresson, ML; Cattan, A | 1 |
Christensen, IJ; Hansen, HH; Roed, H; Spang-Thomsen, M; Vindelov, LL | 1 |
16 review(s) available for arginine and Cancer of Lung
Article | Year |
---|---|
Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Topics: Antineoplastic Agents; Antiviral Agents; Arginine; Butyrates; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Lung Neoplasms; Lung Transplantation; Lymphoproliferative Disorders; Postoperative Complications; Tumor Cells, Cultured; Virus Latency | 2001 |
Tumour-associated hormonal products.
Topics: Adenocarcinoma; Adrenocorticotropic Hormone; Arginine; Biliary Tract Diseases; Bronchial Neoplasms; Carcinoma; Chorionic Gonadotropin; Colonic Neoplasms; Cushing Syndrome; Erythropoietin; Female; Follicle Stimulating Hormone; Growth Hormone; Gynecomastia; Hormones, Ectopic; Humans; Hypercalcemia; Lactation Disorders; Lung Neoplasms; Luteinizing Hormone; Models, Biological; Neoplasms; Paraganglioma; Paraneoplastic Endocrine Syndromes; Polycythemia; Pregnancy; Prolactin; Thyroid Neoplasms; Vasopressins | 1974 |
Disorders of antidiuretic hormone secretion.
Topics: Arginine; Diabetes Insipidus; Diuresis; Humans; Hyponatremia; Lung Neoplasms; Pituitary Diseases; Pituitary Gland, Posterior; Vasopressins; Water-Electrolyte Balance | 1968 |
Chemotherapy for brain metastases from small cell lung cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Cisplatin; Cranial Irradiation; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Teniposide; Topotecan | 2012 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.
Topics: Animals; Antineoplastic Agents; Etoposide; Hodgkin Disease; Humans; Leukemia, Lymphoid; Lung Neoplasms; Podophyllotoxin; Teniposide | 1980 |
New antineoplastic agents in lung cancer 1988-1993.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Teniposide; Vinblastine; Vinorelbine | 1995 |
The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Salvage Therapy; Teniposide; Vincristine | 1995 |
[Chemotherapy of small-cell lung cancer by a combination of teniposide, ifosfamide and carboplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Rate; Teniposide; Treatment Outcome | 1994 |
Teniposide: overview of its therapeutic potential in adult cancers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Etoposide; Female; Genital Neoplasms, Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoma, Kaposi; Teniposide | 1994 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
VM 26 and VP 16-213: a comparative analysis.
Topics: Animals; Brain Neoplasms; Drug Evaluation; Etoposide; Humans; Kinetics; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms, Experimental; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms | 1977 |
Teniposide in the treatment of small cell lung cancer: a review.
Topics: Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Teniposide | 1992 |
Teniposide alone and in combination chemotherapy in small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Humans; Lung Neoplasms; Teniposide | 1992 |
A phase II study with teniposide (VM26) in patients with progressed or relapsed small cell lung cancer (SCLC).
Topics: Adult; Aged; Carcinoma, Small Cell; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Retrospective Studies; Teniposide | 1989 |
41 trial(s) available for arginine and Cancer of Lung
Article | Year |
---|---|
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Arginine; Biomarkers; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Leukocytes, Mononuclear; Lung Neoplasms; Mice | 2022 |
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).
Topics: Arginine; Cachexia; Female; Glutamine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2021 |
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Arginine; Argininosuccinate Synthase; Biomarkers, Tumor; Citrullinemia; Disease-Free Survival; DNA Methylation; Endpoint Determination; Female; Humans; Hydrolases; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Polyethylene Glycols; Treatment Outcome | 2017 |
No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk.
Topics: Age Factors; Arginine; Case-Control Studies; Codon; Female; Genes, p53; Genetic Code; Genetic Markers; Genotype; Humans; Lung Neoplasms; Male; Massachusetts; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Risk Factors; Serine; Smoking; Statistics as Topic | 2003 |
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Glutamic Acid; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Quinazolines; Treatment Outcome | 2006 |
[Clinical studies on the effect of sodium arginate on radiation esophagitis and proctitis].
Topics: Adult; Aged; Arginine; Clinical Trials as Topic; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proctitis; Radiation Injuries; Uterine Neoplasms | 1985 |
Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival; Teniposide; Treatment Outcome; Vincristine | 2002 |
[Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Teniposide; Treatment Outcome | 2002 |
[Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Teniposide | 2004 |
Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Teniposide | 2008 |
Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
Topics: Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Drug Evaluation; Humans; Lung Neoplasms; Phosphonoacetic Acid; Random Allocation; Teniposide; Zinostatin | 1984 |
[New antineoplastic drugs of the podophyllotoxin derivative group].
Topics: Adult; Child; Clinical Trials as Topic; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms | 1983 |
The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Teniposide | 1994 |
A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Recombinant Proteins; Teniposide; Thrombocytopenia; Treatment Outcome | 1994 |
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexa
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Palliative Care; Prospective Studies; Quality of Life; Surveys and Questionnaires; Survival Rate; Teniposide; Vincristine | 1995 |
[VM-26 plus CCNU in the prevention of brain metastasis in lung cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Teniposide | 1995 |
The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Salvage Therapy; Teniposide; Vincristine | 1995 |
Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Small Cell; Cranial Irradiation; Europe; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Remission Induction; Teniposide; Thrombocytopenia; Tomography, X-Ray Computed | 1995 |
Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Teniposide | 1994 |
Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Disease-Free Survival; Factor Analysis, Statistical; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Diseases; Proportional Hazards Models; Survival Rate; Teniposide; Topoisomerase II Inhibitors | 1996 |
Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drugs, Investigational; Female; Gallium; Humans; Imides; Infusions, Intravenous; Isoquinolines; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Naphthalimides; Organophosphonates; Survival Rate; Teniposide | 1995 |
Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Regression Analysis; Remission Induction; Survival Rate; Teniposide; Vincristine | 1996 |
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Teniposide | 1996 |
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival; Teniposide; Treatment Outcome | 1997 |
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group.
Topics: Actuarial Analysis; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Teniposide; Treatment Outcome | 1997 |
A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients wit
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis; Teniposide; Treatment Outcome; Vincristine | 1997 |
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Random Allocation; Survival Rate; Teniposide; Treatment Outcome | 1998 |
[New perspectives in the treatment of bronchial cancer. Pan-European Lung Cancer Forum: "New perspectives on the Management of Lung Cancer". Sitges/Barcelona, 14 March 1998].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cisplatin; Humans; Lung Neoplasms; Paclitaxel; Teniposide | 1998 |
Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Teniposide; Tomography, X-Ray Computed; Treatment Outcome | 1998 |
Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
Topics: Adult; Aged; Alanine Transaminase; Alkenes; Antibiotics, Antineoplastic; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Polyenes; Pyrones; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
Teniposide sometimes effective in brain metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiography; Teniposide; Tomography, Emission-Computed; Treatment Outcome | 1999 |
The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Costs and Cost Analysis; France; Humans; Lung Neoplasms; Netherlands; Paclitaxel; Spain; Teniposide | 1999 |
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Teniposide | 2000 |
Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Mesna; Middle Aged; Prospective Studies; Survival Analysis; Teniposide; Treatment Outcome; Vincristine | 2001 |
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Topics: Alopecia; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Evaluation; Etoposide; Humans; Leukemia; Leukopenia; Lung Neoplasms; Lymphoma; Podophyllotoxin; Teniposide | 1979 |
Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial.
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Glioma; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Podophyllotoxin; Teniposide | 1977 |
Teniposide (VM-26) and carboplatin as initial therapy for small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Survival Rate; Teniposide; Thrombocytopenia | 1992 |
The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Synergism; Europe; Humans; Lung Neoplasms; Remission Induction; Teniposide; Thrombocytopenia | 1992 |
Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.
Topics: Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Prospective Studies; Teniposide | 1991 |
Treatment of extensive small cell lung cancer with carboplatin and teniposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinoma, Small Cell; Drug Evaluation; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Teniposide; Thrombocytopenia | 1991 |
148 other study(ies) available for arginine and Cancer of Lung
Article | Year |
---|---|
An integrated metabonomics study to reveal the inhibitory effect and metabolism regulation of taurine on breast cancer.
Topics: Animals; Arginine; Breast Neoplasms; Choline; Female; Glutamic Acid; Histidine; Humans; Isoleucine; Lactic Acid; Leucine; Lung Neoplasms; Metabolomics; Mice; Taurine; Valine | 2022 |
Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model.
Topics: Amino Acids; Arginine; Carcinoma, Non-Small-Cell Lung; Glycine; Humans; Immune Checkpoint Inhibitors; Leukocytes, Mononuclear; Lung Neoplasms; Neopterin; Pilot Projects; Prognosis; Quinolinic Acids; Tryptophan | 2022 |
Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells.
Topics: Animals; Apoptosis; Arginase; Arginine; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Geobacillus; Humans; Hydrolases; Lung Neoplasms; Mice; Polyethylene Glycols; Stomach Neoplasms | 2022 |
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer.
Topics: Apoptosis; Arginine; Carcinoma, Non-Small-Cell Lung; Caspase 8; Caspases; Genome-Wide Association Study; Humans; Ligands; Lung Neoplasms; Lysine; Sincalide; TNF-Related Apoptosis-Inducing Ligand | 2022 |
[Mechanism of Cordyceps militaris against non-small cell lung cancer: based on serum metabolomics].
Topics: Alanine; Animals; Arginine; Aspartic Acid; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cordyceps; Glutamic Acid; Glutamine; Glyoxylates; Humans; Lung Neoplasms; Metabolomics; Mice; Mice, Nude; Nitrogen; Phenylalanine; RNA, Transfer; Tryptophan; Tyrosine | 2022 |
Chiral Ruthenium Nanozymes with Self-Cascade Reaction Driven the NO Generation Induced Macrophage M1 Polarization Realizing the Lung Cancer "Cocktail Therapy".
Topics: Arginine; Humans; Lung Neoplasms; Macrophages; Nitric Oxide; Reactive Oxygen Species; Ruthenium | 2023 |
Predicting lung adenocarcinoma prognosis, immune escape, and pharmacomic profile from arginine and proline-related genes.
Topics: Adenocarcinoma of Lung; Arginine; Cell Line; Humans; Lung Neoplasms; Prognosis; Tumor Microenvironment | 2023 |
Carbonized polymer dots derived from metformin and L-arginine for tumor cell membrane- and mitochondria-dual targeting therapy.
Topics: Apoptosis; Arginine; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Humans; Lung Neoplasms; Metformin; Mitochondria; Reactive Oxygen Species | 2023 |
C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts.
Topics: Animals; Arginine; Benzhydryl Compounds; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Complement C3; Cytokines; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Complement; Signal Transduction | 2020 |
Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer.
Topics: A549 Cells; Animals; Arginase; Arginine; Bacterial Proteins; Drug Stability; Geobacillus; Half-Life; Humans; Hydrolases; Injections, Intraperitoneal; Lung Neoplasms; Mice; Models, Molecular; Mutation; Polyethylene Glycols; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy.
Topics: Arginine; Calcium Phosphates; Carcinoma, Non-Small-Cell Lung; Cyclin B1; Humans; Lung Neoplasms; Nanoparticles; RNA, Small Interfering; Survivin | 2020 |
PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7.
Topics: Arginine; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Methylation; Prognosis; Protein-Arginine N-Methyltransferases; Smad7 Protein; STAT3 Transcription Factor | 2021 |
Immunohistochemical Expression of Serine and Arginine-Rich Splicing Factor 1 (SRSF1) in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Study.
Topics: Arginine; Asbestos, Amphibole; Biomarkers, Tumor; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; RNA Splicing Factors; Serine; Serine-Arginine Splicing Factors | 2021 |
Topics: Acetic Acid; Albumins; Alkaline Phosphatase; Alkaloids; Amyloid beta-Peptides; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Antioxidants; Aortic Valve; Aortic Valve Stenosis; Apoptosis; Arginine; Autophagy; Bacterial Proteins; Blood Vessel Prosthesis Implantation; Bone Marrow; Brain; Capsaicin; Cartilage, Articular; Cell Differentiation; Cell Wall; Cells, Cultured; Chlorine; Chromatography, High Pressure Liquid; Chromatography, Liquid; Corn Oil; Dioxins; Disinfectants; Enzyme Stability; Enzymes, Immobilized; Escherichia coli O157; Extracellular Vesicles; Female; Food Contamination; gamma-Aminobutyric Acid; Gelatin; Glutamate Decarboxylase; Glutathione; Health Surveys; Heart Valve Prosthesis; Hemodynamics; Humans; Hypertension; Hypoxia; Infant, Newborn; Lactobacillus plantarum; Listeria; Loop of Henle; Lung Neoplasms; Male; Membranes, Artificial; Mesenchymal Stem Cells; Metabolome; Nitric Oxide; Nuclear Magnetic Resonance, Biomolecular; Opioid-Related Disorders; Oryza; Osteoblasts; Osteogenesis; Oxidants; Oxidative Stress; Plant Extracts; Polychlorinated Dibenzodioxins; Polylysine; Polysaccharides, Bacterial; Polyvinyls; Postoperative Complications; Pregnancy; Prescription Drug Misuse; Prosthesis Design; Protein Conformation; Proteins; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Rats, Wistar; Retrospective Studies; Risk Assessment; Risk Factors; Saccharomyces cerevisiae; Silver; Skull; Sodium Chloride; Sodium Chloride, Dietary; Sodium Glutamate; Spectrometry, Mass, Electrospray Ionization; Spinacia oleracea; Superoxide Dismutase; Superoxides; Swine; Swine, Miniature; Tandem Mass Spectrometry; Thiobarbituric Acid Reactive Substances; Time Factors; Tissue Engineering; Tissue Scaffolds; Transfection; Transforming Growth Factor beta1; Treatment Outcome; Wettability; X-Ray Microtomography | 2021 |
Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models.
Topics: Adenocarcinoma; Animals; Apoptosis; Arginase; Arginine; Biomarkers, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Ornithine; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Arginase; Arginine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Oxidative Stress; Recombinant Proteins; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2018 |
Increased plasma concentration of 4-pyridone-3-carboxamide-1-ß-D-ribonucleoside (4PYR) in lung cancer. Preliminary studies.
Topics: Aged; Arginine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Endothelial Cells; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Nucleosides; Pyridones; Tandem Mass Spectrometry | 2019 |
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Topics: Animals; Arginine; Cell Line, Tumor; Disease Models, Animal; Energy Metabolism; Humans; Lung Neoplasms; Metabolic Networks and Pathways; Mice; Mice, Transgenic; Models, Biological; Proto-Oncogene Proteins c-myc; Signal Transduction; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2019 |
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2013 |
Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
Topics: Amino Acid Motifs; Arginine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Isotope Labeling; Lung Neoplasms; Lysine; Mutation; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteome; Proteomics; Signal Transduction | 2013 |
The codon 399 Arg/Gln XRCC1 polymorphism is associated with lung cancer in Indians.
Topics: Adenocarcinoma; Arginine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Codon; DNA; DNA-Binding Proteins; Female; Follow-Up Studies; Genetic Predisposition to Disease; Genotype; Glutamine; Humans; India; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prognosis; Risk Factors; Survival Rate; X-ray Repair Cross Complementing Protein 1 | 2013 |
PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer.
Topics: Amino Acid Sequence; Animals; Arginine; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; DNA Methylation; Epithelial-Mesenchymal Transition; Fluorescent Antibody Technique, Indirect; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Molecular Sequence Data; Neoplasm Invasiveness; Nuclear Proteins; Protein-Arginine N-Methyltransferases; Real-Time Polymerase Chain Reaction; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sequence Homology, Amino Acid; Tumor Cells, Cultured; Twist-Related Protein 1; Wound Healing; Xenograft Model Antitumor Assays | 2015 |
Effect of polyamine metabolism inhibitors on Lewis lung carcinoma growth and metastasis.
Topics: Animals; Arginase; Arginine; Carcinoma, Lewis Lung; Cell Line, Tumor; Drug Screening Assays, Antitumor; Eflornithine; Female; Lung Neoplasms; Mice, Inbred C57BL; Neoplasm Transplantation; Tumor Burden | 2015 |
Fatty acid modified octa-arginine for delivery of siRNA.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Arginine; Cell Line, Tumor; Cell-Penetrating Peptides; Cytochalasin D; Dose-Response Relationship, Drug; Endocytosis; Fatty Acids; Hep G2 Cells; Humans; Lung Neoplasms; Nanoparticles; RNA, Small Interfering; Sucrose | 2015 |
Reduced arginine availability and nitric oxide synthesis in cancer is related to impaired endogenous arginine synthesis.
Topics: Aged; Amino Acids; Arginine; Carcinoma, Non-Small-Cell Lung; Citrulline; Humans; Lung Neoplasms; Male; Middle Aged; Nitric Oxide | 2016 |
A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Arginine; Breast Neoplasms; Carcinoma, Squamous Cell; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Lung Neoplasms; MCF-7 Cells; Methylation; Neoplasm Invasiveness; Neoplasms; Prognosis; Protein-Arginine N-Methyltransferases; Sequence Analysis, RNA; Transcription, Genetic; Transforming Growth Factor beta | 2017 |
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.
Topics: Arginine; Argininosuccinate Synthase; Cell Line, Tumor; DNA Methylation; Humans; Hydrolases; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Polyamines; Polyethylene Glycols; Promoter Regions, Genetic | 2016 |
Advanced Glycation End-Products Enhance Lung Cancer Cell Invasion and Migration.
Topics: Arginine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Fibronectins; Glycation End Products, Advanced; Humans; Intercellular Adhesion Molecule-1; Interleukin-6; Lung Neoplasms; Lysine; Matrix Metalloproteinase 2; Reactive Oxygen Species; Tumor Necrosis Factor-alpha | 2016 |
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Topics: Amino Acid Substitution; Apoptosis; Arginine; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leucine; Lung Neoplasms; Mitochondria; Mutation; Oxidative Phosphorylation; Protein Structure, Quaternary; Protein Transport; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering | 2008 |
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers, Tumor; Case-Control Studies; Colorectal Neoplasms; Esophageal Neoplasms; Female; Genetic Predisposition to Disease; Genotype; Glutamine; Head and Neck Neoplasms; Humans; Incidence; Isoleucine; Japan; Lung Neoplasms; Male; Methionine; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Proline; Protein Tyrosine Phosphatase, Non-Receptor Type 13; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Risk Factors | 2010 |
Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA.
Topics: Animals; Arginine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chitosan; Drug Carriers; Hemolysis; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Molecular Weight; Polyethylene Glycols; Polymers; RNA, Small Interfering | 2010 |
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers.
Topics: Anthracenes; Arginine; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; DNA Replication; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Propane; Protein-Arginine N-Methyltransferases; Repressor Proteins; RNA, Small Interfering; Urinary Bladder Neoplasms | 2011 |
[Interventional lung assist membrane ventilator. Successful use despite heparin-induced thrombocytopenia type II].
Topics: Aged; Anticoagulants; Arginine; Extracorporeal Membrane Oxygenation; Heparin; Humans; Lung Neoplasms; Male; Perioperative Care; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Count; Postoperative Complications; Pulmonary Disease, Chronic Obstructive; Respiratory Distress Syndrome; Respiratory Insufficiency; Smoking; Sulfonamides; Thrombocytopenia | 2011 |
Sequences prior to conserved catalytic motifs of polysialyltransferase ST8Sia IV are required for substrate recognition.
Topics: Animals; Arginine; Catalytic Domain; Cell Adhesion Molecule-1; Cell Adhesion Molecules; Chlorocebus aethiops; CHO Cells; Conserved Sequence; COS Cells; Cricetinae; Humans; Immunoglobulins; Lung Neoplasms; Mutagenesis; N-Acetylneuraminic Acid; Neural Cell Adhesion Molecule L1; Neuropilin-2; Protein Structure, Tertiary; Sialic Acids; Sialyltransferases; Small Cell Lung Carcinoma; Substrate Specificity | 2012 |
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Argininosuccinate Synthase; Female; Humans; Hydrolases; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Polyethylene Glycols; Skin Neoplasms; Survival Rate; Treatment Outcome | 2012 |
Polymorphism Arg72Pro of p53 confers susceptibility to squamous cell carcinoma of lungs in a North Indian population.
Topics: Aged; Amino Acid Substitution; Arginine; Asian People; Carcinoma, Squamous Cell; Case-Control Studies; Female; Genes, p53; Genetic Predisposition to Disease; Genetics, Population; Genotype; Humans; India; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Proline | 2013 |
Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes.
Topics: Aged; Arginine; Bronchoalveolar Lavage Fluid; Codon; DNA Primers; Female; Gene Deletion; Genes, p53; Genotype; Germ-Line Mutation; Heterozygote; Humans; Loss of Heterozygosity; Lung Neoplasms; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Polymorphism, Genetic; Proline; Sputum; Tumor Suppressor Protein p53; Tumor Virus Infections | 2002 |
[An antimetastatic study of Arg-Asp (RD) on salivary adenoid cystic carcinoma in vivo].
Topics: Animals; Antineoplastic Agents; Arginine; Aspartic Acid; Carcinoma, Adenoid Cystic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Salivary Gland Neoplasms | 2002 |
P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21.
Topics: Aged; Alleles; Arginine; Cell Culture Techniques; Codon; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; RNA, Messenger | 2003 |
Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk.
Topics: Adult; Aged; Alleles; Arginine; Aspartic Acid; Codon; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Environment; Female; Genetic Predisposition to Disease; Genotype; Glutamic Acid; Glutamine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Risk; Risk Factors; Smoking; X-ray Repair Cross Complementing Protein 1 | 2004 |
Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis.
Topics: Adenocarcinoma; Alleles; Amino Acid Sequence; Animals; Arginine; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Cysteine; Disease Models, Animal; DNA Mutational Analysis; Genetic Linkage; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Lung Neoplasms; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multifactorial Inheritance; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Receptors, Growth Factor; Receptors, Thrombin; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
The transport of cationic amino acids in human airway cells: expression of system y+L activity and transepithelial delivery of NOS inhibitors.
Topics: Adenocarcinoma; Amino Acid Transport System y+L; Amino Acids; Animals; Arginine; Biological Transport; Cations; Cell Line; Cell Line, Tumor; Cell Membrane Permeability; Culture Media, Conditioned; Epithelial Cells; Gene Expression; Humans; Lung Neoplasms; Lysine; Macrophages; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; omega-N-Methylarginine; Respiratory System; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
Topics: Aged; Alleles; Arginine; Carcinoma, Non-Small-Cell Lung; Codon; Female; Gene Frequency; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Polymorphism, Genetic; Proline; Regression Analysis; Survival Analysis; Tumor Suppressor Protein p53 | 2005 |
Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Arginine; Case-Control Studies; Confounding Factors, Epidemiologic; Cysteine; DNA Repair; Europe, Eastern; Female; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polymorphism, Genetic; Research Design; Risk Assessment; Risk Factors; Selection Bias; Serine; Smoking; Tryptophan | 2005 |
Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer.
Topics: Aged; Anticoagulants; Arginine; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Liver; Liver Function Tests; Lung Neoplasms; Male; Partial Thromboplastin Time; Pipecolic Acids; Sulfonamides; Time Factors; Venous Thrombosis | 2005 |
The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Arginine; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; China; DNA Helicases; DNA Repair; DNA-Binding Proteins; Ethnicity; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Risk Factors; Sex Factors; Smoking; Transcription Factors; Xeroderma Pigmentosum Group D Protein | 2005 |
Comment: extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer.
Topics: Aged; Anticoagulants; Arginine; Humans; International Normalized Ratio; Kidney; Kidney Function Tests; Liver; Lung Neoplasms; Partial Thromboplastin Time; Pipecolic Acids; Sulfonamides; Venous Thrombosis; Warfarin | 2005 |
Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase.
Topics: Adenocarcinoma; Arginine; Breast Neoplasms; Humans; Hydrolases; Lung Neoplasms; Neoplasms; Nitric Oxide; Nitric Oxide Synthase; Polyamines; Protein Biosynthesis; Tumor Cells, Cultured | 2006 |
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Topics: Adenocarcinoma; Arginine; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Genetic Predisposition to Disease; Genotype; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Proline; Risk Factors; Tumor Suppressor Protein p53 | 2006 |
Association between polymorphisms of DNA repair gene XRCC1 and DNA damage in asbestos-exposed workers.
Topics: Adult; Aged; Amino Acid Substitution; Arginine; Asbestos; Comet Assay; DNA Damage; DNA Repair; DNA-Binding Proteins; Genotype; Glutamine; Humans; Hydrogen Peroxide; Lung Neoplasms; Lymphocytes; Middle Aged; Occupational Exposure; Polymerase Chain Reaction; Polymorphism, Genetic; X-ray Repair Cross Complementing Protein 1 | 2006 |
Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Arginine; Carcinoma, Squamous Cell; Codon; Cyclin-Dependent Kinase Inhibitor p21; Female; Genetic Variation; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Proline; Risk Factors; Serine; Smoking; Tumor Suppressor Protein p53 | 2007 |
Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
Topics: Arginine; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; DNA Mutational Analysis; ErbB Receptors; Humans; Leucine; Lung Neoplasms; Mutation; Nucleic Acid Denaturation; Sensitivity and Specificity | 2006 |
Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers, Tumor; Carcinoma, Small Cell; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Records; Middle Aged; Multivariate Analysis; Osmotic Pressure; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Vasopressins | 2007 |
Contrasting impact of DNA repair gene XRCC1 polymorphisms Arg399Gln and Arg194Trp on the risk of lung cancer in the north-Indian population.
Topics: Amino Acid Substitution; Arginine; Case-Control Studies; Codon; DNA Repair; DNA-Binding Proteins; Female; Genotype; Glutamine; Humans; India; Lung Neoplasms; Male; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Population; Risk; Tryptophan; X-ray Repair Cross Complementing Protein 1 | 2007 |
Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
Topics: Amino Acid Substitution; Arginine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Glycine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Receptor, Fibroblast Growth Factor, Type 4; Survival Analysis | 2007 |
An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.
Topics: Alleles; Aneuploidy; Animals; Arginine; Cell Transformation, Neoplastic; Centrosome; Disease Models, Animal; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glycine; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Mutation; ras Proteins; Skin Neoplasms; Tumor Suppressor Protein p53 | 2007 |
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Topics: Aged; Alleles; Arginine; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Codon; DNA Mutational Analysis; Female; Gene Frequency; Genetic Carrier Screening; Genetic Predisposition to Disease; Genotype; Homozygote; Humans; Lung Neoplasms; Male; Middle Aged; Norway; Polymorphism, Single Nucleotide; Proline; Smoking; Tumor Suppressor Protein p53 | 2007 |
Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Topics: Adenocarcinoma; Animals; Antigens, Polyomavirus Transforming; Arginine; Cell Transformation, Neoplastic; Disease Models, Animal; Disease Progression; Female; Genes, p53; Histidine; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Transgenic; Mutation, Missense; Oncogenes; Phenotype; Point Mutation; Tumor Suppressor Protein p53 | 2008 |
Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Arginine; Carcinoma, Non-Small-Cell Lung; Codon; Female; Gene Frequency; Genes, p53; Genotype; Homozygote; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Proline; Survival Rate | 2008 |
Degradation of HPV20E6 by p53: Delta Np63 alpha and mutant p53R248W protect the wild type p53 mediated caspase-degradation.
Topics: Apoptosis; Arginine; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; DNA-Binding Proteins; Glutathione Transferase; Humans; Immunoprecipitation; Lung Neoplasms; Mass Spectrometry; Mutation; Oncogene Proteins, Viral; Papillomavirus Infections; Trans-Activators; Transcription Factors; Tryptophan; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Tumor Virus Infections; Ubiquitin; Vimentin | 2008 |
[Studies on platelet aggregation induced by human cultured carcinoma cell lines].
Topics: Arginine; Cell Line; Cells, Cultured; Female; Humans; Lung Neoplasms; Membrane Proteins; Microbial Collagenase; Neoplasms; Neoplastic Cells, Circulating; Neuraminidase; Pipecolic Acids; Platelet Aggregation; Stomach Neoplasms; Sulfonamides; Trypsin | 1984 |
Effect of antioxidants and antitoxicants of isoniazid on the formation of lung tumours in mice by isoniazid and hydrazine sulphate.
Topics: Animals; Antioxidants; Arginine; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Folic Acid; Hydrazines; Isoniazid; Lung Neoplasms; Mice; Neoplasms, Experimental; Pyridoxine; Sodium Glutamate | 1982 |
Prevention of isoniazid tumorigenicity by antitoxicants of isoniazid in Swiss mice.
Topics: Adenocarcinoma; Ammonia; Animals; Arginine; Folic Acid; Isoniazid; Kidney; Liver; Lung; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Protein Biosynthesis; Pyridoxine; Sodium Glutamate | 1980 |
Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells.
Topics: Amino Acid Oxidoreductases; Animals; Apoptosis; Arginine; Enzyme Induction; Female; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Recombinant Fusion Proteins; Specific Pathogen-Free Organisms; Transfection; Tumor Cells, Cultured | 1995 |
Carboxypeptidase M activity is increased in bronchoalveolar lavage in human lung disease.
Topics: Alanine; Arginine; Bronchoalveolar Lavage Fluid; Cell Count; Cell Membrane; Dansyl Compounds; Female; GPI-Linked Proteins; Humans; Inclusion Bodies; Lung Diseases; Lung Neoplasms; Male; Metalloendopeptidases; Microscopy, Electron; Middle Aged; Myelin Sheath; Phosphorus; Pneumonia; Pneumonia, Pneumocystis; Precipitin Tests; Pulmonary Alveoli; Pulmonary Surfactants | 1995 |
Effect of an inhibitor of nitric oxide synthase on neural relaxation of human bronchi.
Topics: Amino Acid Oxidoreductases; Animals; Arginine; Bronchi; Chymotrypsin; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; In Vitro Techniques; Isoproterenol; Lung Neoplasms; Male; Methacholine Chloride; Middle Aged; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitroprusside; Trachea; Vasoactive Intestinal Peptide | 1993 |
Effects of NG-nitro-L-arginine and/or L-arginine on experimental pulmonary metastasis in mice.
Topics: Animals; Arginine; Drug Synergism; Lung Neoplasms; Male; Melanoma, Amelanotic; Melanoma, Experimental; Mice; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Nitric Oxide; Skin Neoplasms; Specific Pathogen-Free Organisms | 1994 |
NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Antineoplastic Agents; Arginine; Capillary Permeability; Combined Modality Therapy; Female; Immunotherapy; Interleukin-2; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Neoplasm Transplantation; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pleural Effusion, Malignant; Pulmonary Edema; Statistics, Nonparametric; Tumor Cells, Cultured | 1996 |
Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history.
Topics: Arginine; Base Sequence; Case-Control Studies; Disease Susceptibility; Female; Genes, p53; Genotype; Heterozygote; Homozygote; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Polymorphism, Genetic; Proline; Smoking | 1996 |
Tumor cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo.
Topics: Analysis of Variance; Animals; Arginine; Cell Division; Cell Survival; Endotoxins; Enzyme Inhibitors; Female; Humans; Interferon-gamma; Lipopolysaccharides; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Tumor Cells, Cultured | 1996 |
Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Alleles; Amino Acid Sequence; Arginine; Carcinoma; Carcinoma, Small Cell; Codon; Female; Gene Deletion; Gene Frequency; Genes, p53; Genetic Predisposition to Disease; Genotype; Glutathione Transferase; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Proline; Risk Factors; Smoking; Spain | 1996 |
Interaction of truncated human interferon gamma variants with the interferon gamma receptor: crucial importance of Arg-129.
Topics: Antiviral Agents; Arginine; Binding Sites; Encephalomyocarditis virus; Endopeptidases; Escherichia coli; Humans; Interferon gamma Receptor; Interferon-gamma; Kinetics; Lung Neoplasms; Mass Spectrometry; Peptide Fragments; Protein Binding; Receptors, Interferon; Recombinant Proteins; Tumor Cells, Cultured; Virus Replication | 1997 |
Increase in experimental pulmonary metastasis in mice by L-arginine under inhibition of nitric oxide production by NG-nitro-L-arginine methyl ester.
Topics: Animals; Arginine; Arterioles; Blood Platelets; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Platelet Aggregation; Specific Pathogen-Free Organisms; Venules | 1998 |
Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients.
Topics: Adenocarcinoma; Aged; Alleles; Arginine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Codon; Disease Susceptibility; Female; Genes, p53; Genetic Carrier Screening; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Point Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Proline; Risk Factors; Smoking | 1998 |
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arginine; Aspergillosis; Butyrates; Cyclophosphamide; Doxorubicin; Drug Synergism; Enzyme Induction; Epstein-Barr Virus Infections; Fatal Outcome; Ganciclovir; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Lung Neoplasms; Lung Transplantation; Necrosis; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Thymidine Kinase; Tumor Cells, Cultured; Vincristine; Viral Nonstructural Proteins | 1998 |
Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Topics: Animals; Anti-Mullerian Hormone; Arginine; Cell Division; Eye Neoplasms; Female; Fibrinolysin; Glycoproteins; Growth Inhibitors; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, SCID; Mullerian Ducts; Mutagenesis, Site-Directed; Recombinant Proteins; Serine; Testicular Hormones; Transfection; Tumor Cells, Cultured | 1995 |
Affinity purification of recombinant interferon-alpha on a mimetic ligand adsorbent.
Topics: Adsorption; Antiviral Agents; Arginine; Chromatography, Affinity; Chromatography, Gel; Chromatography, High Pressure Liquid; Coloring Agents; Electrophoresis, Polyacrylamide Gel; Encephalomyocarditis virus; Escherichia coli; Humans; Inclusion Bodies; Interferon Type I; Ligands; Lung Neoplasms; Molecular Mimicry; Protein Folding; Recombinant Proteins; Tumor Cells, Cultured | 1999 |
Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding.
Topics: Arginine; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Electrophoresis; Humans; Interferon Regulatory Factor-1; Lung Neoplasms; Phosphoproteins; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Transcription, Genetic; Transfection; Tryptophan; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1999 |
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Humans; Lung Neoplasms; Melanoma; Molecular Sequence Data; Neoplasms; Peptide Fragments; Phosphoprotein Phosphatases; Point Mutation; Protein Binding; Protein Phosphatase 2; Protein Structure, Secondary; Tryptophan | 2001 |
Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes.
Topics: Animals; Arginine; Blotting, Western; Coculture Techniques; Concanavalin A; Cytotoxicity Tests, Immunologic; Female; Lipopolysaccharides; Lung Neoplasms; Lymphocyte Activation; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; T-Lymphocytes; Tumor Cells, Cultured; Tumor Escape | 2001 |
Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma.
Topics: Adenocarcinoma; Aged; Alleles; Arginine; Carcinoma, Squamous Cell; Case-Control Studies; Codon; Female; Genes, p53; Genetic Predisposition to Disease; Genotype; Glutathione Transferase; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Proline | 2001 |
A novel Arg-Gly-Asp containing peptide specific for platelet aggregation and its effect on tumor metastasis: a possible mechanism of RGD peptide-mediated inhibition of tumor metastasis.
Topics: Animals; Anticarcinogenic Agents; Arginine; Aspartic Acid; Carcinoma, Squamous Cell; Cell Adhesion; Collagen; Female; Fibronectins; Glycine; Glycoproteins; Lung Neoplasms; Mice; Mice, Inbred C3H; Neoplasm Metastasis; Oligopeptides; Peptides, Cyclic; Platelet Aggregation; Protein Binding; Vitronectin | 1992 |
Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells.
Topics: Aged; Aged, 80 and over; Antithrombins; Arginine; Blood Coagulation; Cell Death; Cytotoxicity, Immunologic; Female; Fibrin; Fibrinogen; Humans; Immunity, Cellular; Interleukin-2; Killer Cells, Lymphokine-Activated; Kinetics; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Pipecolic Acids; Sulfonamides; Thrombin | 1992 |
H1(0) histones of normal and cancer human cells. Amino acid composition of H1 purified by polyacrylamide gel electrophoresis.
Topics: Amino Acids; Arginine; Carcinoma, Hepatocellular; Cell Line; Histones; Humans; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Lysine; Neoplasms | 1986 |
Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone.
Topics: Adolescent; Adult; Arginine; Blood; Carcinoma, Small Cell; Cyclophosphamide; Humans; Leukemia, Lymphoid; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Osmolar Concentration; Peripheral Nervous System Diseases; Prednisone; Radioimmunoassay; Sodium; Urine; Vasopressins; Vincristine | 1973 |
Arginine-rich low molecular peptides in human neoplastic serum.
Topics: Arginine; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Molecular Weight; Neoplasms; Peptides; Rectal Neoplasms | 1974 |
Failure to induce tumors in Swiss mice after concurrent administration of amino acids and sodium nitrite.
Topics: Adenoma; Animals; Arginine; Carcinogens; Female; Hydroxyproline; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Nitrites; Nitroso Compounds; Piperidines; Proline; Pyrrolidines | 1972 |
Arginine content in serum protein and in serum protein fractions in cases of neoplastic disease.
Topics: Arginine; Blood Protein Electrophoresis; Brain Neoplasms; DNA; Esophageal Neoplasms; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasms; Serum Albumin; Serum Globulins; Uterine Neoplasms | 1971 |
Patterns of amino-acid inhibition of alkaline phosphatases as an aid in cancer diagnosis.
Topics: Adenocarcinoma; Alanine; Alkaline Phosphatase; Amino Acids; Animals; Arginine; Colonic Neoplasms; Female; Humans; In Vitro Techniques; Isoenzymes; Lung Neoplasms; Mammary Neoplasms, Experimental; Neoplasms; Phenylalanine; Rats; Valine | 1971 |
[Radioimmunoassay of arginine vasopressin].
Topics: Animals; Antibodies, Anti-Idiotypic; Arginine; Carcinoma, Bronchogenic; Humans; Lung Neoplasms; Lysine; Rabbits; Radioimmunoassay; Vasopressins | 1971 |
Failure of arginine glutamate to inhibit lung tumor formation by isoniazid and hydrazine in mice.
Topics: Animals; Arginine; Glutamates; Hydrazines; Isoniazid; Liver; Lung; Lung Neoplasms; Male; Mice; Neoplasms, Experimental | 1970 |
The induction of pulmonary neoplasms in mice by isonicotinic acid hydrazide.
Topics: Animal Feed; Animals; Arginine; Body Weight; Carcinogens; Cell Nucleus; Cytoplasm; Feeding Behavior; Female; Glutamates; Isoniazid; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Sodium Chloride | 1971 |
Inappropriate antidiuresis and carcinoma of the lung: detection of arginine vasopressin in tumor extracts by immunoassay.
Topics: Arginine; Carcinoma; Female; Humans; Hyponatremia; Immunoassay; In Vitro Techniques; Lung Neoplasms; Middle Aged; Natriuresis; Tissue Extracts; Vasopressins | 1966 |
Phase II study of teniposide in small cell carcinoma of the lung.
Topics: Adult; Aged; Carcinoma, Small Cell; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Teniposide | 1984 |
Sequential half-body irradiation (SHBI) and combination chemotherapy as salvage treatment for failed Ewing's sarcoma--a pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Child; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Sarcoma, Ewing; Teniposide; Whole-Body Irradiation | 1984 |
Combination chemotherapy for metastatic brain tumors.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Doxorubicin; Drug Therapy, Combination; Humans; Lomustine; Lung Neoplasms; Nitrosourea Compounds; Podophyllotoxin; Prognosis; Teniposide; Tomography, X-Ray Computed | 1981 |
Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship.
Topics: Adenocarcinoma; Cell Line; Cell Survival; DNA; DNA Repair; Etoposide; Humans; Kinetics; Lung Neoplasms; Podophyllotoxin; Structure-Activity Relationship; Teniposide | 1984 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Melanoma; Mice; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Rats; Razoxane; Teniposide | 1982 |
Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice.
Topics: Animals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Half-Life; Kinetics; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Podophyllotoxin; Teniposide; Tissue Distribution | 1983 |
Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.
Topics: Amsacrine; Antineoplastic Agents; Carcinoma, Small Cell; Cell Fractionation; Cell Line; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Exons; Genes, myc; Humans; Lung Neoplasms; Restriction Mapping; Saline Solution, Hypertonic; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Teniposide for meningeal carcinomatosis of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Immunologic Factors; Injections, Spinal; Interferon-gamma; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Morphine; Teniposide; Vincristine | 1993 |
Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
Topics: Amsacrine; Carcinoma, Small Cell; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance; Humans; Lung Neoplasms; Teniposide; Tumor Cells, Cultured | 1993 |
[In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Division; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1993 |
Combination chemotherapy with teniposide (VM26) and carboplatin in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis; Teniposide | 1993 |
Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cadmium; Cadmium Chloride; Carcinoma, Small Cell; Cell Line; Chlorides; Cisplatin; Cross Reactions; DNA; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Humans; Lung Neoplasms; Metallothionein; Platinum Compounds; Podophyllotoxin; Teniposide; Tumor Cells, Cultured; Vinca Alkaloids | 1996 |
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
Topics: Amsacrine; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Multiple; Humans; In Situ Hybridization, Fluorescence; Isoenzymes; Lung Neoplasms; Mitoxantrone; Multidrug Resistance-Associated Proteins; RNA, Messenger; RNA, Neoplasm; Teniposide; Tumor Cells, Cultured | 1996 |
The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Marrow; Carcinoma, Small Cell; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Nausea; Neoplasm Staging; Remission Induction; Survival Rate; Teniposide; Thrombocytopenia; Vomiting | 1997 |
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Mathematical Computing; Teniposide; Treatment Outcome | 1998 |
Improved high-performance liquid chromatographic analysis of teniposide in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Humans; Lung Neoplasms; Male; Spectrophotometry, Ultraviolet; Teniposide | 1998 |
[VP-16 and VM-26 plus platinum drugs combined with radiotherapy in the treatment of small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Teniposide | 1998 |
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Isoenzymes; Ki-67 Antigen; Life Tables; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation, Missense; Neoplasm Proteins; Paclitaxel; Point Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Teniposide; Topotecan; Treatment Outcome; Vault Ribonucleoprotein Particles | 2001 |
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Carcinoma, Small Cell; Cell Survival; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Guanosine Triphosphate; Humans; Lung Neoplasms; Nucleoside Deaminases; Teniposide; Thymidine Kinase; Tumor Cells, Cultured; Uridine Triphosphate | 2001 |
[Controversial treatment of brain metastases of small-cell lung cancer. Randomized comparison of chemotherapy alone and radiochemotherapy].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Neurologic Examination; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Teniposide; Treatment Outcome | 2001 |
Paclitaxel and lung cancer: new preparation. No therapeutic progress.
Topics: Antineoplastic Agents, Phytogenic; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Teniposide; Treatment Outcome | 2000 |
[Chemotherapy of non-small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas and nitric oxide (NO) levels].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Epirubicin; fas Receptor; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitric Oxide; Teniposide; Treatment Outcome | 2000 |
[Palliative irradiation combined with chemotherapy for lung cancer with brain metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Teniposide; Treatment Outcome | 2001 |
VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Podophyllotoxin; Remission, Spontaneous; Teniposide; Thrombocytopenia | 1978 |
Antimetastasis effect of two derivatives of epiposophyllotoxin in mice.
Topics: Animals; Etoposide; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Podophyllotoxin; Solvents; Teniposide; Time Factors | 1976 |
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line; Cell Survival; Cisplatin; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Phenotype; Restriction Mapping; RNA, Neoplasm; Teniposide | 1992 |
Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile.
Topics: Aged; Attitude to Health; Carcinoma, Small Cell; Etoposide; Follow-Up Studies; Humans; Longitudinal Studies; Lung Neoplasms; Neoplasm Staging; Probability; Quality of Life; Surveys and Questionnaires; Teniposide | 1992 |
Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Topics: Amsacrine; Animals; Base Sequence; Binding Sites; Carcinoma, Small Cell; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Genes, myc; Humans; Leukemia L1210; Lung Neoplasms; Mice; Molecular Sequence Data; Promoter Regions, Genetic; Restriction Mapping; Substrate Specificity; Teniposide | 1992 |
Phase I study of oral teniposide (VM-26).
Topics: Administration, Oral; Adult; Aged; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Remission Induction; Teniposide; Thrombocytopenia; Vomiting | 1992 |
Treatment of brain metastases of small cell lung cancer with teniposide.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Teniposide; Thrombocytopenia | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Leukemia; Lung Neoplasms; Novobiocin; RNA; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
Teniposide as single drug therapy for elderly patients affected by small cell lung cancer.
Topics: Aged; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Teniposide; Treatment Outcome | 1992 |
Mitomycin C, teniposide, and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Teniposide | 1991 |
Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Teniposide | 1991 |
Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Cell Line; Colonic Neoplasms; DNA; DNA Damage; DNA Probes; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Membrane Glycoproteins; Molecular Sequence Data; Neoplasm Proteins; Porfiromycin; RNA; Teniposide | 1991 |
Pilot study of teniposide in combination chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Pilot Projects; Teniposide; Vincristine | 1991 |
Phase II study of teniposide in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Remission Induction; Teniposide; Thrombocytopenia | 1991 |
Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
Topics: Aged; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Podophyllotoxin; Teniposide | 1990 |
Cytotoxic effects of teniposide combined with cis-diammine-dichloroplatinum (II) on the in vitro Lewis lung carcinoma model: influence of the treatment schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Drug Interactions; Lung Neoplasms; Teniposide; Tumor Cells, Cultured | 1989 |
Treatment strategies in relation to drug action.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Etoposide; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Podophyllotoxin; Teniposide | 1987 |
Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Pericardial Effusion; Pericardium; Podophyllotoxin; Teniposide | 1987 |
The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Organoplatinum Compounds; Teniposide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1988 |
Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung.
Topics: Aged; Brain Neoplasms; Carcinoma, Small Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Teniposide; Thrombocytopenia | 1988 |
Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.
Topics: Aged; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Prognosis; Teniposide | 1988 |
Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC).
Topics: Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Evaluation; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Teniposide | 1988 |
Podophyllotoxins for brain metastases of small cell lung cancer.
Topics: Brain Neoplasms; Carcinoma, Small Cell; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Teniposide | 1988 |
Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
Topics: Aged; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Teniposide | 1986 |
DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Small Cell; Cell Division; Cell Nucleus; Cells, Cultured; DNA; DNA, Single-Stranded; Drug Resistance; Etoposide; Humans; Intercalating Agents; Lung Neoplasms; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors | 1986 |
A case of small cell lung cancer successfully treated with VM26.
Topics: Aged; Carcinoma, Small Cell; Drug Evaluation; Humans; Lung Neoplasms; Male; Podophyllotoxin; Teniposide | 1986 |
Teniposide in the treatment of non-small cell lung carcinoma.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Teniposide | 1987 |
Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
Topics: Animals; Body Weight; Cell Count; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Etoposide; Kinetics; Leukocyte Count; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Podophyllotoxin; Teniposide | 1986 |
Vitamin A: failure to demonstrate in mice an anti-tumour effect, whether combined with cytotoxic drugs or not.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Female; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Teniposide; Vitamin A | 1986 |
The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Lung Neoplasms; Podophyllotoxin; Teniposide | 1987 |
Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Cells, Cultured; DNA; DNA Repair; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide | 1985 |